CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
VEGF-C D2-40 E-Cad在乳腺癌中的表达及意义
Authors
冯水土
张永兴
郑志高
陈毅德
Publication date
15 December 2009
Publisher
Abstract
目的:探讨VEGF-C、D2-40、E-Cad在乳腺癌中的表达及意义。方法:采用免疫组织化学方法,检测临床病理及随访资料完整的88例乳腺浸润性导管癌及54例导管内增生性病变组织中VEGF-C的表达情况,分析其与D2-40、E-Cad表达的关系及其临床病理意义.结果:VEGF-C在浸润癌组的阳性表达率显著性强于不典型增生组和普通型增生组;同时淋巴结转移组显著性强于无淋巴结转移组;乳腺癌变组LVD明显高于乳腺不典型增生组和普通型增生组,淋巴结转移阳性组LVD计数明显高于淋巴结转移阴性组;E-Cad在浸润癌组中的阳性表达率明显低于不典型增生组及普通型增生组,淋巴结转移组显著性低于无淋巴结转移组,VEGF-C与D2-40呈正相关,与E-Cad呈负相关。结论:VEGF-C与D2-40的联合检测可以作为临床评价肿瘤早期淋巴道转移的重要指标;VEGF-C与E-Cad的联合使用可作为乳腺癌预后的重要指标
Similar works
Full text
Available Versions
Xiamen University Institutional Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:dspace.xmu.edu.cn:2288/181...
Last time updated on 16/06/2016